ZIOP-PGEN Fundamental & Technical Discussion Board - Competitors in TCR-T -- Iova, Intellia, TCRR and Timmunity - ZIOP-PGEN Fundamental & Technical Discussion Board - InvestorVillage


ZIOP-PGEN Fundamental & Technical Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: ZIOP-PGEN Fundamental & Technical Discussion Board   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  25206 of 25524  at  10/27/2021 5:06:43 PM  by

clsm

The following message was updated on 11/15/2021 2:00:11 PM.

 In response to msg 25205 by  dachmeister4u
view thread

Re: Competitors in TCR-T -- Iova, Intellia, TCRR and Timmunity

IOVA: They already have two pivotal trials and could file BLAs next year. In addition, a number of others, including using PD-1+ TIL and PD-1 knockout 'bulk' TIL.

NTLA: They are in the clinic with an auto TCR-T targeting WT1 (expanding into solids within the next few years). Healthy donor CAR-T's are preclinical, with sequential editing for both. Also, they use CRISPR as a screening tool to identify novel edits that enhance trafficking, infiltration, potency, persistence and overcome exhaustion in a range of immunosuppressive TMEs. In addition, are expanding the 'toolbox' with base editing https://www.globenewswire.com/news-release/2021/03/25/2199184/0/en/Intellia-Therapeutics-Presents-New-Data-
on-Expanded-Cell-Engineering-Capabilities-Utilizing-Base-Editors.html


TCRR: Next year a PhII will start in four types, with MPM able to move into a seamless pivotal trial. They have a number of next-gen enhancements, such mbIL-15 and a PD-1 'switch' https://cancerres.aacrjournals.org/content/80/16_Supplement/893

Tmunity Therapeutics: NY-ESO-1 isn't a neoantigen. As for pipeline, it is mostly CAR-T's, with them building a library of constructs to overcome the barriers faced like immunosuppressive TMEs. Also, they are working on allo and CRISPR/Cas9 edited.

With your last paragraph, CRSP should file a BLA in beta thalassaemia and sickle cell disease in the next 12-18 months.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...